株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

膵炎:パイプライン製品の分析

Pancreatitis - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 246013
出版日 ページ情報 英文 74 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.47円で換算しております。
Back to Top
膵炎:パイプライン製品の分析 Pancreatitis - Pipeline Review, H2 2017
出版日: 2017年09月19日 ページ情報: 英文 74 Pages
概要

膵炎は膵臓の炎症であり、症状には上腹部痛、吐き気、嘔吐、腹部に触れた際の圧痛、および体重減少などがあります。発病の要因にはアルコール依存症、喫煙、膵炎の家族歴、感染症、腹部の損傷および膵臓癌が含まれます。治療には抗生物質および痛みを緩和するための薬物療法などが用いられます。

当レポートでは、膵炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

膵炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

膵炎:企業で開発中の治療薬

膵炎:大学/機関で研究中の治療薬

膵炎:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

膵炎:企業で開発中の製品

膵炎:大学/機関で研究中の製品

膵炎の治療薬開発に従事している企業

  • Angion Biomedica Corp.
  • Atox Bio Inc.
  • Bharat Serums And Vaccines Limited
  • CalciMedica, Inc.
  • Dynavax Technologies Corporation
  • Generon (Shanghai) Corporation Ltd.
  • GlaxoSmithKline Plc
  • Pharming Group N.V.

膵炎:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

膵炎:最近のパイプライン動向

膵炎:休止中のプロジェクト

膵炎:開発が中止された製品

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9720IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H2 2017, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape.

Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 2, 1, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pancreatitis - Overview
    • Pancreatitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Pancreatitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pancreatitis - Companies Involved in Therapeutics Development
    • Angion Biomedica Corp
    • Bharat Serums And Vaccines Ltd
    • CalciMedica Inc
    • Cypralis Ltd
    • Dynavax Technologies Corp
    • Generon (Shanghai) Corp Ltd
    • GlaxoSmithKline Plc
    • LipimetiX Development Inc
    • Novartis AG
    • Pharming Group NV
    • Sarfez Pharmaceuticals Inc
    • Sun BioPharma Inc
    • Takeda Pharmaceutical Company Ltd
  • Pancreatitis - Drug Profiles
    • AAD-2004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-2802 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-2814 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANG-3070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C1 esterase inhibitor (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-128 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-4620 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DV-1179 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-652 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-180 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2795039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3335065 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-428 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-6288B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-2pal18S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptides to Agonize RNLS for Acute Pancreatitis, Acute Kidney Injury and Cisplatin Induced Kidney Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Cyclophilin D for Acute Pancreatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit KMO for Pancreatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Soluble Epoxide Hydrolase for Acute Pancreatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Trypsin for Pancreatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-20201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-671 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ulinastatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Withaferin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pancreatitis - Dormant Projects
  • Pancreatitis - Discontinued Products
  • Pancreatitis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 10, 2017: Sun BioPharma Provides Clinical Update
      • May 24, 2017: CalciMedica Receives Fast-Track Designation for CM4620, a Novel CRAC Channel Inhibitor to Treat Acute Pancreatitis
      • Feb 01, 2017: The NIH Awards Sun BioPharma Grant to Study SBP-101 for the Treatment of Pancreatitis
      • Jan 05, 2017: CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor
      • Oct 24, 2016: Sun BioPharma to Present at the Innovation Biotech Showcase on October 26th
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Pancreatitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pancreatitis - Pipeline by Angion Biomedica Corp, H2 2017
  • Pancreatitis - Pipeline by Bharat Serums And Vaccines Ltd, H2 2017
  • Pancreatitis - Pipeline by CalciMedica Inc, H2 2017
  • Pancreatitis - Pipeline by Cypralis Ltd, H2 2017
  • Pancreatitis - Pipeline by Dynavax Technologies Corp, H2 2017
  • Pancreatitis - Pipeline by Generon (Shanghai) Corp Ltd, H2 2017
  • Pancreatitis - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Pancreatitis - Pipeline by LipimetiX Development Inc, H2 2017
  • Pancreatitis - Pipeline by Novartis AG, H2 2017
  • Pancreatitis - Pipeline by Pharming Group NV, H2 2017
  • Pancreatitis - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017
  • Pancreatitis - Pipeline by Sun BioPharma Inc, H2 2017
  • Pancreatitis - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Pancreatitis - Dormant Projects, H2 2017
  • Pancreatitis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Pancreatitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top